Hinge Health is navigating a curious post-earnings divergence: the stock is up 12% on the week yet short sellers are quietly rebuilding positions, even as every analyst who has touched the name in the past week has raised their target.
The short interest story has shifted notably since the Q2 print. Back in early July, short interest peaked near 9.2 million shares. It then fell sharply through the earnings event, dropping to around 15.3% of the free float by early August — a retreat consistent with shorts covering ahead of results. That unwinding has now reversed. Short interest jumped 10% in a single session on August 11, bringing it back to 16.1% of the free float. Over the week, the position has grown by 5.7%. The monthly picture still shows a 29% decline from the July highs, so the rebuild is partial rather than a full reversal — but the directional shift is clear. Borrow conditions do not explain the move: the lending pool remains extremely loose, with availability at roughly 1,685% of short interest. That means there are approximately 28.7 million shares available to lend against 6.1 million already short. Cost to borrow has also eased, falling 21% on the week to just 0.37%. These are not the conditions of a stressed borrow market. Shorts are adding exposure by choice, not being forced out. Options traders have become more cautious in parallel. The put/call ratio has climbed to 1.04, running about 1.6 standard deviations above its 20-day average of 0.69. That is the most defensive options posture the stock has seen since late July, when the ratio was tracking below 0.55. The shift in the PCR and the short rebuild are pointing in the same direction: parts of the market are hedging or fading the post-earnings rally.
The Street itself is moving the other way. After the Q2 beat, a wave of target increases landed — all raises, no cuts. Truist Securities was the most recent to act, lifting its target to $112 on August 11. The consensus mean now sits at $105, implying roughly 18% upside from the current $89 close. Every recent analyst action has been a raise, and the bull case centres on Hinge Health's AI-driven musculoskeletal platform, FDA progress on migraine treatment, and expanding market reach. Bears are more focused on timeline: meaningful financial impact from new products is not expected until 2027, operating margin targets do not depend on pricing expansion, and migraine utilisation data is still largely outstanding. Valuation is a legitimate constraint — the stock trades at a P/E of 31x and a price-to-book above 14x, both having drifted higher over the past week as the stock rallied. The EV/EBITDA multiple of 23.5x has eased about 3 points over the past month, which is the one multiple moving in a constructive direction. Factor scores are mixed: the days-to-cover rank sits in the 76th percentile and the utilisation rank in the 72nd, reflecting high short interest relative to liquidity, while EPS momentum over 30 days ranks just in the 21st percentile.
Insider activity adds one more layer to read carefully. The 90-day net insider position is technically positive at 1.85 million shares, but that reflects a large share award to CEO Daniel Perez on July 27 — 944,250 shares awarded at zero cost. Against that, Perez sold 509,423 shares the same week, realising $37.9 million at $74.31. Executive Chairman Gabriel Mecklenburg sold 509,423 shares on August 4 at $77.65, banking $39.6 million. The CFO and President both sold smaller tranches on July 31. The pattern is consistent with planned selling into the post-IPO price appreciation rather than a signal of deteriorating conviction, but the volume of executive selling — over $77 million combined from the two founders in a single fortnight — is worth noting against a backdrop of shorts rebuilding positions. BlackRock added 2.66 million shares as of July 31, a significant institutional accumulation, providing a counterweight to the insider flow.
The next earnings event is scheduled for November 5. Between now and then, the key tension to watch is whether the short rebuild continues at pace — and whether that shifts borrow conditions from today's extremely loose state toward something tighter — or whether the stock's momentum and the unanimously bullish analyst posture absorb the new selling pressure.
See the live data behind this article on ORTEX.
Open HNGE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
